What Biortus does

Biortus Biosciences Co., Ltd. (佰翱得) is a privately held contract research organization founded in 2009 and headquartered in Jiangyin, China, with a secondary US office (Boston area). The company provides a one-stop structural biology service for drug discovery, spanning gene synthesis, recombinant protein production (mammalian, insect baculovirus, E. coli, and cell-free expression systems), biochemical, biophysical, and cell-based assay development, compound screening, X-ray crystallography, and Cryo-EM (including Single Particle Analysis, MicroED for small molecules, and lipid nanoparticle drug delivery characterization). It serves pharmaceutical and biotechnology companies as its primary customer segment, with academic and research institutions as a secondary segment, and operates with 251-500 employees.

Biortus's core technology stack combines wet-lab structural biology infrastructure with BiortusAI, an AI/ML computational platform launched in 2025 that adds generative and retrieval-based capabilities for protein design, antibody design, and hit discovery. The company maintains a product catalogue of 6,000+ recombinant proteins, 300+ membrane proteins, 30+ assay kits, and 20+ tool enzymes, including specialized offerings such as Biortus MagBox affinity chromatography reagents and membrane protein expression systems. Credibility is reinforced by co-authorship in more than 10 publications in top-tier journals (Science, Cell, Cell Research, Nature Communications, JACS), and the company has active partnerships including a collaboration with SPT Labtech on cryo-EM sample preparation.

Biortus generates revenue primarily through fee-for-service CRO contracts (project-based or milestone-based pricing) and catalogue product sales, distributed through a sales-led, direct enterprise motion targeting pharma and biotech customers. The company has raised approximately $46.3 million across a 2020 Series A and 2021 Series B from institutional healthcare investors including Bayland Capital, Kangjun Capital, Legend Capital, and Sherpa Healthcare Partners, and supports its commercial outreach through participation in industry conferences such as BioJapan 2025 and Discovery on Target 2025.

Name

Biortus

Legal name

Biortus Biosciences Co.,Ltd.

Website

https://en.wuxibiortus.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

251–500 employees

Short description

Biortus Biosciences (佰翱得) is a China-based contract research organization founded in 2009 that provides integrated structural biology, protein production, assay, and cryo-EM services to pharmaceutical, biotechnology, and academic clients, and recently added the BiortusAI platform for AI/ML-powered protein, antibody, and hit discovery design.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Contract research services
• Structural biology
• Protein production
• Cryo-EM services
• Drug discovery

Headquarters

HQ city

Jiangyin

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Biortus provides fee-for-service CRO offerings including protein production, assay development, compound screening, X-ray crystallography, and cryo-EM structure determination. Services are billed on a project basis, likely with per-service or milestone-based pricing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Biortus is a contract research organization (CRO) providing one-stop services from gene synthesis to cryo-EM structure determination for drug discovery. Core capabilities include target protein production, biochemical/biophysical/cellular assay development, compound screening and characterization, X-ray crystallography, and cryo-EM for protein structure determination. The company also sells catalog products including recombinant proteins, assay kits, and tool enzymes, and operates the proprietary BiortusAI platform that integrates artificial intelligence into structural biology workflows.

Product overview

Biortus is a contract research organization offering a one-stop service from gene synthesis to structure determination for drug discovery. The company operates as a platform-plus-services model combining BiortusAI (AI/ML computational platform for protein/antibody/hit design) with wet-lab services including protein production, assay development and screening, X-ray crystallography, and Cryo-EM. The product portfolio includes 6000+ recombinant proteins, 30+ assay kits, 20+ tool enzymes, and specialized products like Biortus MagBox for affinity purification. Services target pharmaceutical and biotechnology companies across all stages of biomedical research.

Differentiator

Problem solved

Functional benefit

Products and services

• BiortusAI Platform

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

One partnership is on record.

• SPT LabtechnotableTechnology or IntegrationBiortus partnered with SPT Labtech on cryo-EM sample preparation, combining Biortus's expertise in protein engineering with SPT Labtech's advanced Chameleon system for cryo-EM sample preparation. This collaboration was highlighted in a joint case study.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• WuXi AppTec: The dominant China-headquartered CRO/CDMO offering end-to-end discovery, preclinical, and clinical services. Overlaps with Biortus on protein production, structural biology, and in vitro pharmacology and competes for the same large-pharma outsourcing budgets from a much larger scale base.
• Charles River Laboratories: Global, publicly listed CRO/CDMO with broad discovery, safety assessment, and manufacturing services. Overlaps with Biortus on protein/structural biology work via its Early Discovery portfolio and represents the scale-and-breadth benchmark Biortus competes against for large pharma preferred-vendor agreements.
• Eurofins Discovery: Part of Eurofins Scientific's life sciences services network, providing drug discovery services including in vitro pharmacology, ADME, and protein sciences. Competes with Biortus for mid- and large-pharma discovery outsourcing and offers a wider geographic footprint.
• Evotec: European-headquartered drug discovery CRO offering biology, chemistry, and integrated target-to-candidate services. Overlaps with Biortus on assay development, screening, and structural biology and is increasingly pairing wet-lab capabilities with AI/ML platforms.
• Thermo Fisher Scientific (Pharma Services): Diversified life sciences tools and CRO/CDMO business with protein production, structural biology, and drug discovery offerings. Operates at materially larger scale than Biortus across the same buyer set and represents the integrated strategic-vendor alternative.

Direct peers

• Pharmaron: China-origin, globally integrated CRO providing discovery, chemistry, biology, DMPK, and safety assessment services. Directly comparable to Biortus on protein sciences and in vitro pharmacology and offers a broader service menu to the same pharma/biotech buyer cohort.
• GenScript: Global life sciences services and products company with deep capabilities in gene synthesis, recombinant protein production, and antibody engineering. Directly competes with Biortus on protein production services and reagent catalogues for the same biotech customers.
• Viva Biotech: Structure-based drug discovery CRO offering cryo-EM, X-ray crystallography, protein production, and computational chemistry services. Closest peer to Biortus on structural biology-led discovery services with a highly overlapping customer base.
• Medicilon: China-based preclinical CRO providing protein production, bioanalytical, in vitro and in vivo pharmacology, and IND-enabling services. Competes with Biortus on the protein sciences and in vitro pharmacology portion of integrated discovery programs.

Regional players

• Syngene International: India-based integrated CRO providing discovery, development, and manufacturing services to global pharma. Comparable service profile to Biortus (biology, structural biology, protein sciences) but primarily serves US/European clients from a non-China base, making it a substitute rather than direct geographic competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/biortususa
• Facebookfacebook.com/biortususa
• LinkedInlinkedin.com/company/biortus/posts/?feedView=all
• Instagraminstagram.com/biortususa

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biortus